Define Ventures Appoints Carolyn Magill as Venture Partner
Define Ventures, a major early-stage health tech venture capital firm, has appointed Carolyn Magill as venture partner. Magill brings 25 years of experience in healthcare, having served as CEO of Aetion and Remedy Partners, and held executive positions at Evolent Health and UnitedHealth Group.
Magill joins existing venture partners Bruce Broussard (former Humana CEO) and Frank Williams (Evolent Health co-founder) to support Define's portfolio companies. The firm, managing $800 million in assets, invests in seed to series B stage companies and has backed notable ventures like Hims & Hers.
Her expertise spans payer, provider, and pharmaceutical sectors, with particular focus on data and AI applications. At Aetion, she led a platform transforming real-world data into regulatory-grade evidence, while at Remedy Partners she oversaw bundled payments software and services.
Define Ventures, una importante società di venture capital nel settore della salute in fase iniziale, ha nominato Carolyn Magill come partner di venture. Magill porta con sé 25 anni di esperienza nel settore sanitario, avendo ricoperto il ruolo di CEO di Aetion e Remedy Partners, e ha ricoperto posizioni dirigenziali presso Evolent Health e UnitedHealth Group.
Magill si unisce ai partner di venture esistenti Bruce Broussard (ex CEO di Humana) e Frank Williams (co-fondatore di Evolent Health) per supportare le aziende del portafoglio di Define. La società, che gestisce 800 milioni di dollari in asset, investe in aziende dalla fase seed alla fase B e ha sostenuto iniziative note come Hims & Hers.
La sua esperienza spazia tra i settori dei pagatori, dei fornitori e farmaceutici, con particolare attenzione alle applicazioni di dati e intelligenza artificiale. Presso Aetion, ha guidato una piattaforma che trasforma i dati del mondo reale in prove di grado regolatorio, mentre presso Remedy Partners ha supervisionato software e servizi di pagamenti aggregati.
Define Ventures, una importante firma de capital de riesgo en tecnología de salud en etapas tempranas, ha nombrado a Carolyn Magill como socia de riesgo. Magill aporta 25 años de experiencia en el sector de la salud, habiendo sido CEO de Aetion y Remedy Partners, y ocupando puestos ejecutivos en Evolent Health y UnitedHealth Group.
Magill se une a los socios de riesgo existentes Bruce Broussard (ex CEO de Humana) y Frank Williams (cofundador de Evolent Health) para apoyar a las empresas del portafolio de Define. La firma, que gestiona 800 millones de dólares en activos, invierte en empresas desde la etapa seed hasta la serie B y ha respaldado iniciativas notables como Hims & Hers.
Su experiencia abarca los sectores de pagadores, proveedores y farmacéuticos, con un enfoque particular en aplicaciones de datos e inteligencia artificial. En Aetion, lideró una plataforma que transforma datos del mundo real en evidencia de grado regulatorio, mientras que en Remedy Partners supervisó software y servicios de pagos agrupados.
Define Ventures는 주요 초기 단계 헬스테크 벤처 캐피탈 회사로, Carolyn Magill을 벤처 파트너로 임명했습니다. Magill은 Aetion과 Remedy Partners의 CEO로 재직하며 25년의 헬스케어 경험을 쌓았고, Evolent Health와 UnitedHealth Group에서 임원직을 역임했습니다.
Magill은 기존 벤처 파트너인 Bruce Broussard(전 Humana CEO) 및 Frank Williams(Evolent Health 공동 창립자)와 함께 Define의 포트폴리오 회사를 지원합니다. 이 회사는 8억 달러의 자산을 관리하며, 시드 단계에서 시리즈 B 단계의 회사에 투자하고 Hims & Hers와 같은 주목할 만한 벤처를 지원했습니다.
그녀의 전문 분야는 지불자, 제공자 및 제약 부문을 아우르며, 데이터 및 AI 응용 프로그램에 특히 중점을 두고 있습니다. Aetion에서는 실제 데이터를 규제 기준의 증거로 변환하는 플랫폼을 이끌었으며, Remedy Partners에서는 패키지 결제 소프트웨어 및 서비스를 감독했습니다.
Define Ventures, une importante société de capital-risque dans le domaine des technologies de la santé à un stade précoce, a nommé Carolyn Magill en tant que partenaire de capital-risque. Magill apporte 25 ans d'expérience dans le secteur de la santé, ayant été PDG d'Aetion et de Remedy Partners, et ayant occupé des postes de direction chez Evolent Health et UnitedHealth Group.
Magill rejoint les partenaires de capital-risque existants Bruce Broussard (ancien PDG de Humana) et Frank Williams (co-fondateur d'Evolent Health) pour soutenir les entreprises du portefeuille de Define. La société, qui gère 800 millions de dollars d'actifs, investit dans des entreprises allant de la phase d'amorçage à la phase B et a soutenu des initiatives notables telles que Hims & Hers.
Son expertise couvre les secteurs des payeurs, des fournisseurs et de la pharmacie, avec un accent particulier sur les applications de données et d'intelligence artificielle. Chez Aetion, elle a dirigé une plateforme transformant des données du monde réel en preuves conformes aux réglementations, tandis que chez Remedy Partners, elle a supervisé des logiciels et des services de paiements groupés.
Define Ventures, eine bedeutende Venture-Capital-Firma im Bereich Gesundheitstechnologie in der Frühphase, hat Carolyn Magill zur Venture-Partnerin ernannt. Magill bringt 25 Jahre Erfahrung im Gesundheitswesen mit, nachdem sie als CEO von Aetion und Remedy Partners tätig war und leitende Positionen bei Evolent Health und UnitedHealth Group innehatte.
Magill schließt sich den bestehenden Venture-Partnern Bruce Broussard (ehemaliger CEO von Humana) und Frank Williams (Mitbegründer von Evolent Health) an, um Define's Portfoliounternehmen zu unterstützen. Die Firma verwaltet 800 Millionen Dollar an Vermögenswerten, investiert in Unternehmen von der Seed- bis zur Series-B-Phase und hat bemerkenswerte Unternehmen wie Hims & Hers unterstützt.
Ihr Fachwissen erstreckt sich über die Bereiche Zahler, Anbieter und Pharmazeutika, mit besonderem Fokus auf Daten- und KI-Anwendungen. Bei Aetion leitete sie eine Plattform, die reale Daten in regulierungsfähige Beweise umwandelt, während sie bei Remedy Partners Software und Dienstleistungen für gebündelte Zahlungen überwachte.
- Strengthened leadership team with addition of experienced healthcare executive
- Strategic expertise across payer, provider, and pharmaceutical sectors
- Substantial $800M assets under management
- Track record of successful investments including NYSE-listed companies
- None.
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors
Carolyn is a seasoned healthcare executive and two-time CEO, having held executive leadership positions across multiple corners of the ecosystem. Prior to joining Define, Carolyn was CEO of Aetion, whose platform transforms real-world data into regulatory-grade evidence for critical healthcare decisions. She also previously served as CEO of Remedy Partners, the premier bundled payments software and services company, and as Executive Vice President of Payer Strategy and Operations at Evolent Health, where she helped drive the company's progression from startup through IPO. She also held several leadership roles at UnitedHealth Group, including Chief Operating Officer of its Community and State plan in
"Carolyn's extensive experience across payer, provider, and pharmaceutical sectors makes her uniquely qualified to guide the next generation of health tech innovators," said Lynne Chou O'Keefe, founder and managing partner at Define Ventures. "Having had the privilege of partnering with Carolyn as an advisor for many years, we're confident her deep expertise, particularly in data and AI applications within the pharmaceutical landscape, will be invaluable to our partner companies."
"Define represents the best of venture — an incredible founder community and a team of experienced operators who truly understand what it takes to build in healthcare," said Magill. "Throughout my career, I've worked across many corners of healthcare, and joining Define allows me to bring that experience to the earliest stages of innovation, helping founders turn ideas into impact."
Carolyn's appointment complements Define Ventures' existing venture partners, Bruce Broussard, former CEO of Humana, and Frank Williams, co-founder and former CEO of Evolent Health, creating a powerful trio of industry leaders with comprehensive experience across payer, provider and pharmaceutical sectors. Together, they bring unparalleled strategic depth to Define's partner companies.
Define Ventures has
To learn more about Define Ventures, visit www.definevc.com.
About Define Ventures
Define Ventures is one of the largest funds focused on early-stage health tech companies. With
View original content to download multimedia:https://www.prnewswire.com/news-releases/define-ventures-appoints-carolyn-magill-as-venture-partner-302397696.html
SOURCE Define Ventures
FAQ
What is Define Ventures' current assets under management?
Who are the current venture partners at Define Ventures?
What is Carolyn Magill's background in healthcare?
Which notable companies are in Define Ventures' portfolio?
